Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quadrivalent subunit influenza vaccine (adjuvanted) (Ab&B Bio-tech)
- Development stage
- Unknown
- Lead developer
- Ab&B Bio-tech Co., Ltd.
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This drug is a quadrivalent subunit influenza vaccine (adjuvanted) developed by Jiangsu Ab&B Bio-tech Co., Ltd. It is designed to provide active immunization against four strains of the influenza virus, typically including two Influenza A subtypes (H1N1 and H3N2) and two Influenza B lineages (Victoria and Yamagata). As a subunit vaccine, it contains purified viral proteins, specifically hemagglutinin (HA), rather than the whole virus, which reduces the risk of adverse reactions while maintaining immunogenicity. The vaccine is formulated with an adjuvant (such as the oil-in-water emulsion MF59) to enhance the magnitude and breadth of the immune response, a feature particularly beneficial for older adults (aged 65 and older) who may have a diminished response to standard vaccines due to immunosenescence. It is administered via a single intramuscular injection.
- Other names
- Quadrivalent Subunit Influenza Vaccine (Adjuvant)Adjuvanted quadrivalent subunit influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Quadrivalent subunit influenza vaccine (adjuvanted) (Ab&B Bio-tech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quadrivalent subunit influenza vaccine (adjuvanted) (Ab&B Bio-tech).